Viridian Therapeutics, Inc.\DE — Form 8-K
Filed November 4, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
Viridian reported Q3 2026 net product revenue of $24.7 million from Lumvoa (veligrotug-vvze) for thyroid eye disease, with over 100 patients on therapy and a permanent CMS J-code assigned effective January 1, 2027. The company maintains $955.2 million in cash and expects to fund operations through profitability. Pipeline advances include elegrobart BLA submission on track for Q1 2027, VRDN-008 phase 1 data expected Q4 2026, and VRDN-292 phase 1 initiation planned Q4 2026.
Why this rating
Early Lumvoa launch exceeds expectations with 100+ patients and meaningful J-code access; revenue represents early proof-of-concept. Strong cash position ($955M, 101% of market cap) enables pipeline advancement. However, Q3 net loss of $101.2M ($333M YTD) indicates path to profitability is years away despite product launch.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.